

Attorney Docket No. COUL-015/02US

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on September 11, 2002.

By: Vikki L. Athen

Vikki L. Athen

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Vincent DUBOIS, et al.

Serial No.: 09/879,442

Examiner: Unassigned

Confirmation No.: 3549

Art Unit: 1646

Filed: June 11, 2001

For: ENZYME-CLEAVABLE PRODRUG COMPOUNDS

RECEIVED

SEP 20 2002

TECH CENTER 1600/2300

Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT TRANSMITTAL**

Enclosed is an Information Disclosure Statement and accompanying Form PTO/SB/08A for the above-identified patent application.

☒ In accordance with 37 C.F.R. §1.97(b), no additional fee for submission of the IDS is required.

☒ A return receipt postcard is also enclosed.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 03-3117.

Dated: September 10, 2002

Respectfully submitted,  
COOLEY GODWARD LLP

Cooley Godward LLP  
ATTN: Patent Group  
Five Palo Alto Square  
3000 El Camino Real  
Palo Alto, CA 94306-2155  
Tel: (650) 843-5000  
Fax: (650) 857-0663


By: Traci H. Ropp

Traci H. Ropp  
Reg. No. 44,307

Attorney Docket No. COUL-015/02US

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on September 11, 2002.



By: \_\_\_\_\_

*Vikki L. Athen*

Vikki L. Athen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Vincent DUBOIS, et al.

Serial No.: 09/879,442

Examiner: Unassigned

Confirmation No.: 3549

Art Unit: 1646

Filed: June 11, 2001

For: ENZYME-CLEAVABLE PRODRUG COMPOUNDS

RECEIVED

SEP 20 2002

TECH CENTER 1600/2900

Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.97(b)**

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56,  
Applicant(s) hereby submits the following information in conformance with 37 C.F.R.  
§§1.97 and 1.98.

- ☒ Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attached Form PTO/SB/08 is enclosed.
- ☒ Publication(s) **D94**, **D95** and **D96** listed on the attached Form PTO/SB/08A were cited in a foreign search or examination report corresponding to PCT application serial no. PCT/US01/18903 and mailed on June 21, 2002.

This Information Disclosure Statement is filed within any one of the following time periods:

- ☒ before the mailing date of a first office action on the merits

In accordance with 37 CFR § 1.97(b), no additional fee for submission of IDS is required.


It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Dated: September 11, 2002


Respectfully submitted,  
**COOLEY GODWARD LLP**

Cooley Godward LLP  
ATTN: Patent Group  
Five Palo Alto Square  
3000 El Camino Real  
Palo Alto, CA 94306-2155  
Tel: (650) 843-5000  
Fax: (650) 857-0663

By:

  
Traci H. Ropp  
Reg. No. 44,307

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>		<b>RECEIVED</b>  SEP 20 2002  TECH CENTER 1800/2900	
				Application Number	09/879,442		
				Filing Date	June 11, 2001		
				First Named Inventor	Vincent DUBOIS		
				Group Art Unit	1646		
				Examiner Name			
Sheet	1	of	1	Attorney Docket Number	COUL-015/02US		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	D94	CAMARGO, A. C. M. et al., "Structural Features That Make Oligopeptides Susceptible Substrates for Hydrolysis by Recombinant Thimet Oligopeptidase", <i>Biochem. J.</i> , 324:517-522 (1997)	
	D95	FERNANDEZ, A-M. et al., "N-Succinyl-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: An Extracellularly Tumor-Activated Prodrug Devoid of Intravenous Acute Toxicity", <i>J. Med. Chem.</i> , 44:3750-3753 (2001)	
	D96	KNIGHT, C. G., "A Quenched Fluorescent Substrate for Thimet Peptidase Containing a New Fluorescent Amino Acid, DL-2-amino-3-(7-methoxy-4-coumaryl)propionic acid", <i>Biochem. J.</i> , 274:45-48 (1991)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number.

<sup>2</sup> Applicant is to place a check mark here if English language Translation attached.